ResMed Inc. (RMD)
| Market Cap | 29.99B -13.4% |
| Revenue (ttm) | 5.54B +10.3% |
| Net Income | 1.52B +15.7% |
| EPS | 10.37 +16.4% |
| Shares Out | 145.06M |
| PE Ratio | 19.94 |
| Forward PE | 17.33 |
| Dividend | $2.40 (1.16%) |
| Ex-Dividend Date | May 14, 2026 |
| Volume | 993,474 |
| Open | 206.79 |
| Previous Close | 206.89 |
| Day's Range | 203.92 - 207.98 |
| 52-Week Range | 198.64 - 293.81 |
| Beta | 0.84 |
| Analysts | Buy |
| Price Target | 288.56 (+39.56%) |
| Earnings Date | Apr 30, 2026 |
About RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring... [Read more]
Financial Performance
In fiscal year 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for RMD stock is "Buy." The 12-month stock price target is $288.56, which is an increase of 39.56% from the latest price.
News
ResMed price target lowered to $225 from $254 at Baird
Baird lowered the firm’s price target on ResMed (RMD) to $225 from $254 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results and
ResMed price target lowered to $235 from $265 at Stifel
Stifel lowered the firm’s price target on ResMed (RMD) to $235 from $265 and keeps a Hold rating on the shares.
ResMed beats quarterly profit estimates, names new CFO
Medical device maker ResMed beat third‑quarter profit estimates on Thursday, driven by strong demand for its medical devices, while appointing Aaron Bloomer as its new chief financial officer.
ResMed CFO Brett Sandercock to retire, Aaron Bloomer to succeed
Resmed (RMD) announced that Brett Sandercock, CFO, plans to retire effective May 4. After conducting a search, Aaron Bloomer has been appointed as his successor. Bloomer joinsResmedfrom Exact Sciences...
ResMed Earnings Call Transcript: Q3 2026
Q3 FY26 saw 11% revenue growth, 21% non-GAAP EPS growth, and strong margin expansion. Announced Noctrix Health acquisition and CFO transition, with robust cash flow and continued investment in innovation and shareholder returns.
ResMed reports Q3 EPS $2.86, consensus $2.72
Reports Q3 revenue $1.43B, consensus $1.42B. “Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined ...
Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett...
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8% GAAP income from operations increased 17%...
ResMed price target lowered to $290 from $302 at KeyBanc
KeyBanc lowered the firm’s price target on ResMed (RMD) to $290 from $302 to reflect lower peer multiples, while keeping an Overweight rating on the shares. The firm believes underlying
ResMed initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of ResMed (RMD) with an Overweight rating and A$37.60 price target The firm says ResMed is the global leader in the obstructive sleep apnea market. While therapeutics,
ResMed price target lowered to $255 from $300 at Evercore ISI
Evercore ISI analyst Anthony Petrone lowered the firm’s price target on ResMed (RMD) to $255 from $300 and keeps an Outperform rating on the shares. The firm adjusted estimates and
ResMed price target lowered to $340 from $345 at Citi
Citi lowered the firm’s price target on ResMed (RMD) to $340 from $345 and keeps a Buy rating on the shares.
Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, ...
Resmed's Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach
Insights from 30,000 people across 13 countries show global sleep health awareness is growing, yet an action gap remains 53% of people surveyed rank sleep as the most important behavior for a long, h...
ResMed At $250: Missed Opportunity Or A Trap In The Making?
ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a company that is demonstrating reasonable growth, maint...
ResMed opens new distribution center in Greenwood, Indiana
Resmed (RMD) is opening a new distribution center in Greenwood, Indiana. Scheduled to begin operations in 2027, the center will expand Resmed’s U.S. presence and strengthen the company’s distribution ...
Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distributi...
Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge
Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling the GLP‑1 bo...
ResMed price target raised to $345 from $330 at Citi
Citi analyst Laura Sutcliffe raised the firm’s price target on ResMed (RMD) to $345 from $330 and keeps a Buy rating on the shares.
ResMed price target raised to $314 from $311 at RBC Capital
RBC Capital analyst Craig Wong-Pan raised the firm’s price target on ResMed (RMD) to $314 from $311 and keeps an Outperform rating on the shares. The company delivered a strong
ResMed price target raised to $302 from $299 at KeyBanc
KeyBanc analyst Brett Fishbin raised the firm’s price target on ResMed (RMD) to $302 from $299 and keeps an Overweight rating on the shares post Q2 on higher estimates. The
ResMed price target raised to $265 from $260 at Stifel
Stifel raised the firm’s price target on ResMed (RMD) to $265 from $260 and keeps a Hold rating on the shares following fiscal Q2 results. While the firm calls it
ResMed price target raised to $281 from $275 at Baird
Baird raised the firm’s price target on ResMed (RMD) to $281 from $275 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results which
ResMed price target raised to $275 from $270 at Piper Sandler
Piper Sandler raised the firm’s price target on ResMed (RMD) to $275 from $270 and keeps a Neutral rating on the shares. The firm notes the company reported Q2 results
ResMed beats quarterly profit estimates on strong demand for its sleep devices
Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep apnea.